Cannabinoid formulation and method of making thereof
AssigneePet Releaf IP, LLC
InventorJoseph Rosentel
Life of this patent
Estimating the term…
Abstract
A formulation for administration to non-human mammals and/or human mammals for the treatment of osteoarthritis includes active ingredients. The active ingredients include (a) an efficacious amount of cannabidiol (“CBD”), a component of a full-spectrum hemp extract (FSHE), or a broad-spectrum hemp extract (BSHE), or a CBD isolate; (b) an efficacious amount of beta-caryophyllene (“BC”); and (c) an efficacious amount caprylic acid (“CA”).
Claims20
A formulation for administration to mammals, the formulation comprising active ingredients, the active ingredients comprising:
- (a) an efficacious amount of a source of cannabidiol (“CBD”), the source of CBD comprising a full-spectrum hemp extract (FSHE), or a broad-spectrum hemp extract (BSHE), or a CBD isolate;
- (b) an efficacious amount of additional beta-caryophyllene (“BC”), the additional BC being in addition to any BC present in the source of the CBD;
- and
- (c) an efficacious amount of additional caprylic acid (“CA”), the additional CA being in addition to any CA present in the source of the CBD.
A capsule for administration to mammals, the capsule comprising:
- (a) an efficacious amount of a source of cannabidiol (“CBD”), the source of the CBD comprising a full-spectrum hemp extract (FSHE), or a broad-spectrum hemp extract (BSHE), or a CBD isolate;
- (b) an efficacious amount of additional beta-caryophyllene (“BC”), the additional BC being in addition to any BC present in the source of the CBD;
- and
- (c) an efficacious amount additional caprylic acid (“CA”), the additional CA being in addition to any CA in the source of the CBD;
- the capsule comprising:
- from 1 to 200 mg of the CBD from the source of the CBD;
- from 1 to 200 mg of the additional BC;
- and
- from 1 to 200 mg of the additional CA.
A method comprising:
- (a) producing a liquid-based mixture comprising:
- (i) a full-spectrum hemp extract oil;
- (ii) additional liquid beta-caryophyllene, the additional liquid beta-caryophyllene being in addition to any beta-caryophyllene in the full-spectrum hemp extract oil;
- (iii) additional liquid caprylic acid, the additional liquid caprylic acid being in addition to any caprylic acid in the full-spectrum hemp extract oil;
- and
- (b) adding a powder-based excipient to the liquid-based mixture, wherein the powder-based excipient absorbs the liquid-based mixture, thereby creating a powder.
Dependencies are inferred from the claim text.